Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery disease.

Coron Artery Dis

aBaylor Heart and Vascular Institute bDepartment of Internal Medicine, Texas A&M Health Science Center, College of Medicine, Dallas Campus cBaylor Scott & White Research Institute dInstitute of Metabolic Disease eDivision of Cardiology, Baylor Jack and Jane Hamilton Heart and Vascular Hospital fDivision of Cardiology, Baylor University Medical Center, Dallas gDivision of Cardiology, Baylor All Saints Medical Center, Fort Worth hDivision of Cardiology, The Heart Hospital Baylor Plano, Plano, Texas iCorgenix Inc., Broomfield, Colorado, USA.

Published: June 2017

Background: Aspirin use is effective in the prevention of cardiovascular disease; however, not all patients are equally responsive to aspirin. Oxidative stress reflected by F2-isoprostane [8-iso-prostaglandin-F2α (8-IsoPGF2α)] is a potential mechanism of failure of aspirin to adequately inhibit cyclooxygenase-1. The objective was to examine the relation between all-cause mortality and the concentrations of urinary 11-dehydro thromboxane B2 (11dhTxB2) and 8-IsoPGF2α in patients with stable coronary artery disease (CAD).

Methods: The data for this analysis are from a prospective study in which patients were categorized into four groups based on the median values of 11dhTxB2 and 8-IsoPGF2α.

Results: There were 447 patients included in this analysis with a median (range) age of 66 (37-91) years. The median (range) values of 11dhTxB2 and 8-IsoPGF2α were 1404.1 (344.2-68296.1) and 1477.9 (356.7-19256.3), respectively. A total of 67 (14.9%) patients died over a median follow-up of 1149 days. The reference group for the Cox proportional hazards survival analysis was patients with values of 11dhTxB2 and 8-IsoPGF2α below their corresponding medians. Adjusting for the age and sex, patients with values of 11dhTxB2 greater than the median had a significantly higher risk of mortality when compared with the reference group (high 11dhTxB2 and low 8-IsoPGF2αadj: hazard ratio: 3.2, 95% confidence interval: 1.6-6.6, P=0.002; high 11dhTxB2 and 8-IsoPGF2αadj: hazard ratio: 3.6, 95% confidence interval: 1.8-7.3, P<0.001). The findings were similar when we adjusted for the comorbidities of cancer, kidney function, and ejection fraction.

Conclusion: We found that 11dhTxB2 appears to be a better prognostic marker for mortality as compared with 8-IsoPGF2α, suggesting aspirin resistance itself is a stronger independent determinant of death in CAD patients treated with aspirin.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MCA.0000000000000461DOI Listing

Publication Analysis

Top Keywords

values 11dhtxb2
16
11dhtxb2 8-isopgf2α
12
oxidative stress
8
patients
8
patients stable
8
stable coronary
8
coronary artery
8
artery disease
8
median range
8
reference group
8

Similar Publications

Reference interval establishment and correlation research of urine thromboxane metabolites: Unveiling new possibilities in platelet activation.

Clin Chim Acta

May 2024

Clinical research department, Dalian Boyuan Medical Technology Co., Ltd, Dalian, China; Department of medical Research, Dalian Runsheng Kangtai Medical Lab Co. Ltd, Dalian, China.

Background: Thromboxane metabolites could indirectly reflect platelet activation, among which 11-dehydro-thromboxane B (11dhTxB) and 11-dehydro-2, 3-dinor thromboxane B (11dh23dinorTxB) are two stable metabolites that are abundant in urine, and both are closely related to disease progression and drug use. However, most clinical application studies have focused on the single indicator of 11dhTxB. We propose an LC-MS/MS method suitable for routine clinical screening with simultaneous determination of both metabolites and conduct preliminary studies in different populations.

View Article and Find Full Text PDF

Objective: To explore the clinical significance and value of serum homocysteine (Hcy) and urine 11 dehydrothromboxane B2 (urine 11-DH-TXB2) combined with transferrin-specific peptide (TF-UP) in the diagnosis of stroke.

Methods: One hundred stroke patients treated from January 2019 to June 2021 were enrolled in our hospital as the study group. All the patients in the study group met the diagnostic criteria of stroke.

View Article and Find Full Text PDF

Introduction: Cigarette smoking is associated with the risk of certain diseases, but non-combustible products may lower these risks. The potential long-term health effects of the next-generation non-combustible products (heat-not-burn tobacco products (HNBP) or electronic vapor products) have not been thoroughly studied. The present study aimed to investigate the impact of biomarkers of potential harm (BoPH) of one of HNBP (a novel vapor product: NTV (novel tobacco vapor)), under the conditions of actual use.

View Article and Find Full Text PDF

Aim: There is a variable cardiovascular risk reduction attributable to aspirin because of individual differences in the suppression of thromboxane A and its downstream metabolite 11-dehydro-thromboxane B (11dhTxB ). The aim of this study is to evaluate the optimal cut point of urinary 11dhTxB for the risk of mortality in aspirin-treated coronary artery disease (CAD) patients.

Methods And Results: This was a prospective cohort study including stable CAD patients who visited the Baylor Heart and Vascular Hospital in Dallas or the Texas Heart Hospital Baylor Plano, TX between 2010 and 2013.

View Article and Find Full Text PDF

In the present study, we evaluated the curative effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor alogliptin combined with motor imagery under hyperbaric oxygen in diabetic nephropathy (DN) with silent cerebral infarction (SCI). Two-hundred newly diagnosed DN patients with and without SCI were included. The SCI patients were divided into two treatment groups: Alogliptin (A group, n=50) and alogliptin combined with motor imagery under hyperbaric oxygen (B group, n=50).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!